Querying automated antibiotic susceptibility testing instruments: A novel population-based active surveillance method for multidrug-resistant gram-negative bacilli

Infection Control and Hospital Epidemiology

Volumn 35, Issue 4, 2014, Pages 336-341

  Reno, Jessica ^a,b,c   Schenck, Calista ^a,b,c   Scott, Janine ^a,b,c   Clark, Leigh Ann ^a,b,c   Wayne Wang, Yun F ^b,d,e   Ray, Susan ^a,b,c,d,e   Vagnone, Paula Snippes ^f   Jacob, Jesse T ^e  

^a ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^b Atlanta Veterans Affairs Medical Center ^*

^c ATLANTA VA MEDICAL CENTER   (United States)

^d GRADY MEMORIAL HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; DORIPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DISEASE SURVEILLANCE; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; MICROBIOLOGY TEST; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PILOT STUDY; DEVICES; GEORGIA; GRAM NEGATIVE BACTERIUM; HEALTH SURVEY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES; URBAN POPULATION;

ANTI-BACTERIAL AGENTS; AUTOMATION, LABORATORY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GEORGIA; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; URBAN POPULATION;

EID: 84895829193     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/675608     Document Type: Article

References (24)

1. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011;17(10): 1791-1798.
2. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42:S82-S89.
3. Jacob JT, Klein E, Laxminarayan R, et al. Vital signs: carbapenemresistant Enterobacteriaceae. MMWR Morb Mortality Wkly Rep 2013;62(9):165-170.
4. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52(3):1028-1033.
5. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City. Arch Intern Med 2005;165:1430-1435.
6. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30(12):1180-1185.
7. Khan AS, Dancer SJ, Humphreys H. Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals. J Hosp Infect 2012;82(2):85-93.
8. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010;65(2):233-238.
9. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8(12):751-762.
10. Sunenshine RH, Wright M-O, Maragakis LL, et al. Multidrugresistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13(1):97-103.
11. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of b-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 US hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 2013;57(7):3012-3020.
12. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006;56(4):367-372.
13. American FactFinder, US Census Bureau website. Annual estimates of the resident population: April 1, 2010, to July 1, 2012; generated by Jessica Reno using American FactFinder, http:// factfinder2.census.gov, May 8, 2013.
14. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. Wayne, PA: CLSI, 2010. CLSI documents M100-S20 and M100-S20-U.
15. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52(3):813-821.
16. Orsi GB, Falcone M, Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther 2011;9(8):653-679.
17. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstreaminfections. Clin Microbiol Infect 2012;18(1):54-60.
18. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099-1106.
19. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30(10):972-976.
20. Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010;67(2):180-184.
21. Hombach M, Wolfensberger A, Kuster SP, Bottger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of gram-negative rods. J Clin Microbiol 2013;51(7): 2385-2387.
22. Hombach M, Bloemberg GV, Bottger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of gramnegative bacilli. J Antimicrob Chemother 2012;67(3):622-632.
23. Tamma PD, Wu H, Gerber JS, et al. Outcomes of children with Enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? Pediatr Infect Dis J 2013;32(9):965-969.
24. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters 2013, version 3.1. http://www.eucast.org. Accessed August 16, 2013.